Company intelligence / Profile preview

MultiCell Immunotherapeutics

Woonsocket, Rhode Island, United States

Ownership: Private
Development stage: Other

Overview

MultiCell Immunotherapeutics developed antibody-drug conjugates (ADCs) for cancer treatment. The company's ADC platform technology featured unique multivalent, cleavable linkers allowing drugs to be released intracellularly or extracellularly upon antibody binding to target cells. In March 2015, MCIT signed an agreement with Oxis Biotech to develop three novel ADCs for triple-negative breast cancer and multiple myeloma treatment.

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugate
Industry: Biotech

Partnerships

Research & development and product license agreement signed in March 2015 with Oxis Biotech to create three novel antibody-drug conjugates for triple-negative breast cancer and multiple myeloma. Terms included $500,000 license fee, up to $1.125 million in development cost reimbursement, up to $12.75 million in clinical development milestones, $10 million option for manufacturing rights, and 3% royalty on net yearly sales.

Beyond the preview

Go deeper on MultiCell Immunotherapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MultiCell Immunotherapeutics.